Growth Dynamics on Exocrine Pancreatic Insufficiency Therapeutics Market 2019-2026| Key Players : AzurRx , AbbVie Inc. , CHIESI FarmaceuticiS.p.A. , Allergan , Janssen Pharmaceuticals Inc.

The global exocrine pancreatic insufficiency therapeutics market to reach USD 2.55 billion by 2026, exhibiting a CAGR of 6.5% during the forecast period. Increasing prevalence of diabetes worldwide is touted to be one of the core factors fueling the growth of this market. According to the International Diabetes Federation (IDF), in 2019, approximately 463 million adults were suffering from diabetes and by 2045, this figure will rise to 700 million. In the same year, the disease caused deaths of 4.2 million people and around 374 million people are at an increased risk of developing type 2 diabetes. Diabetes cause micro vascular damage which reduce pancreatic volume, inducing pancreatic fibrosis. According to the National Institutes of Health, those afflicted by type 1 diabetes have a 30 to 50% chance of developing exocrine pancreatic insufficiency, while those with type 2 have a 20 to 30% chance of developing the disorder. Thus, the exocrine pancreatic insufficiency therapeutics market stands to gain as a result.

Request a Sample Copy of the Research Report:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/exocrine-pancreatic-insufficiency-market-100652

The report covers :
o Global exocrine pancreatic insufficiency therapeutics market trends, with detailed analysis on consumer trends & manufacturer trends.
o Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
o Key areas of investments identifying market opportunities and challenges in forecast time frame.
o Competitive analysis of the industry players along with the overview on strategic management.
o Comprehensive company profiles of the major industry players.

An Overview of the Impact of COVID-19 on this Market :
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.
Click here to get the short-term and long-term impact of COVID-19 on this [Market].

Please visit : https://www.fortunebusinessinsights.com/industry-reports/exocrine-pancreatic-insufficiency-market-100652

Leading Players operating in the Exocrine Pancreatic Insufficiency Therapeutics Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
o AzurRx
o AbbVie Inc.
o CHIESI FarmaceuticiS.p.A.
o Allergan
o Janssen Pharmaceuticals, Inc.

Steady Rise in the Incidence of Disorders Associated with EPI to Aid Growth
There are many conditions associated with exocrine pancreatic insufficiency such as celiac disease, cystic fibrosis, inflammatory bowel diseases, and pancreatic cancer. The prevalence of these associated disorders is on the rise, which is expected to ramp up the demand for exocrine pancreatic insufficiencytreatment. This increasing demand has led to innovation in EPI medications and therapeutics that have enhanced the potential of this market. One of the most popular development in the market is the creation of the Pancreatic Enzyme Replacement Therapy (PERT) which is furthering the exocrine pancreatic insufficiencytherapeutics market trends.

Increasing Incidence of Gastrointestinal Disorders to Drive the Market in North America
Among regions, North America is slated to dominate the exocrine pancreatic insufficiency therapeutics market share in the forecast period, having generated USD 1.18 billion in 2018 in revenue. The main reasons for this is the increasing prevalence and awareness regarding gastrointestinal diseases in the region along with a high adoption rate of advanced treatment methods for EPI. Rising disposable incomes that have increased the uptake of EPI therapeutics would aid Asia-Pacific register the highest growth rate in this market. Awareness about associated disorders is growing speedily in countries such as Japan and India which will feed the market in the region. In Europe, the market is anticipated to be driven by the increasing penetration of exocrine pancreatic insufficiency medications.

Have Any Query? Ask Our Experts :
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/exocrine-pancreatic-insufficiency-market-100652

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges

Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.